Expert Interview
A review of the failed Phase 3 SUPPRESS brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) and analysis of the company's argument that there is a pathway forward for developing the drug
Ticker(s): CMRXHematologic Oncologist specializing in either Multiple Myeloma or Leukemia and consistently performing Hematopoietic Cell transplants. Ideally involved in a trial for brincidofovir Essential that expert is familiar with brincidofovir data to date.
Please briefly go over your relevant clinical experience. How many patients you treat, HCTs per year.
Added By: joe_mccannHow do you currently deal with cytomegalovirus in patients undergoing HCT?
Added By: joe_mccannThe company has stated: "Preliminary analysis suggests that the primary endpoint failures in both the prevention of CMV infections and mortality in the brincidofovir arm were driven by confirmed cases of graft-versus-host-disease (GVHD), which resulted in a significantly higher use of corticosteroids than in the control arm. Both GVHD and use of corticosteroids are risk factors for late CMV infection that occurs after discontinuation of the antiviral in HCT recipients." Is there something about brincidofovir that would cause more GVHD?
Added By: joe_mccannIn your opinion does the totality of the data currently available justify further development in HCT patients?
Added By: joe_mccannThe company has is developing brincidofovir in serious adenovirus infections and in smallpox. Is there anything in this data that would jeopardize the drug in these indication?
Added By: joe_mccannAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
